Sunshine Biopharma Opens $4M ATM Equity Program Amid Cash Crunch
SBFM is trading near its 52-week low of $1.7 (5.9% below the low) on light trading volume (0.1× avg).
Summary
Sunshine Biopharma has entered an at-the-market sales agreement with Aegis Capital to sell up to $4 million of common stock. This follows a $6 million public offering in May and a 1-for-10 reverse split in June, with the company burning cash and trading near its 52-week low of $1.70. The ATM provides a flexible funding source but adds dilution risk at depressed prices. The company's Q1 financials showed worsening losses and a $5.3 million legal dispute, underscoring the need for capital.
At the time of this announcement, SBFM was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $1.70 to $24.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.